Charles M Perou Selected Research

Claudins

1/2022	Chemotherapy Coupled to Macrophage Inhibition Induces T-cell and B-cell Infiltration and Durable Regression in Triple-Negative Breast Cancer.
11/2021	Anti-PD-1 Checkpoint Therapy Can Promote the Function and Survival of Regulatory T Cells.
1/2021	Highly metastatic claudin-low mammary cancers can originate from luminal epithelial cells.
12/2018	DPYSL3 modulates mitosis, migration, and epithelial-to-mesenchymal transition in claudin-low breast cancer.
9/2017	Treg depletion potentiates checkpoint inhibition in claudin-low breast cancer.
1/2017	Metabolic reprogramming underlies metastatic potential in an obesity-responsive murine model of metastatic triple negative breast cancer.
1/2017	Patterns of cell cycle checkpoint deregulation associated with intrinsic molecular subtypes of human breast cancer cells.
3/2016	Overview of Genetically Engineered Mouse Models of Distinct Breast Cancer Subtypes.
1/2016	A high capacity polymeric micelle of paclitaxel: Implication of high dose drug therapy to safety and in vivo anti-cancer activity.
12/2015	Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Charles M Perou Research Topics

Disease

216	Neoplasms (Cancer) 06/2022 - 06/2002
200	Breast Neoplasms (Breast Cancer) 06/2022 - 10/2002
33	Triple Negative Breast Neoplasms 06/2022 - 12/2008
18	Neoplasm Metastasis (Metastasis) 01/2020 - 03/2009
16	Carcinogenesis 12/2021 - 12/2007
13	Pathologic Complete Response 01/2022 - 08/2005
7	Carcinoma (Carcinomatosis) 02/2015 - 01/2006
5	Disease Progression 01/2021 - 01/2006
5	Noninfiltrating Intraductal Carcinoma (DCIS) 01/2020 - 02/2007
4	Melanoma (Melanoma, Malignant) 12/2021 - 10/2012
4	Genomic Instability 01/2017 - 06/2012
3	Lung Neoplasms (Lung Cancer) 01/2016 - 03/2009
3	Squamous Cell Carcinoma of Head and Neck 08/2014 - 05/2004
3	Tics (Tic) 02/2014 - 02/2012
3	Retinoblastoma (Glioblastoma, Retinal) 03/2012 - 01/2008
2	Prostatic Neoplasms (Prostate Cancer) 01/2021 - 12/2006
2	Urinary Bladder Neoplasms (Bladder Cancer) 01/2021 - 01/2021
2	Aneuploidy (Aneuploid) 01/2020 - 01/2004
2	Renal Cell Carcinoma (Grawitz Tumor) 01/2018 - 01/2016
2	Glioma (Gliomas) 12/2015 - 06/2015

Drug/Important Bio-Agent (IBA)

100	Phenobarbital (Luminal)FDA Link 06/2022 - 07/2003
58	Estrogen ReceptorsIBA 06/2022 - 01/2004
47	DNA (Deoxyribonucleic Acid)IBA 06/2022 - 10/2002
39	RNA (Ribonucleic Acid)IBA 06/2022 - 07/2006
35	Proteins (Proteins, Gene)FDA Link 06/2022 - 08/2004
33	Biomarkers (Surrogate Marker)IBA 06/2022 - 05/2004
33	ClaudinsIBA 01/2022 - 05/2009
28	Biological ProductsIBA 01/2022 - 01/2006
21	Messenger RNA (mRNA)IBA 01/2022 - 10/2002
21	Progesterone Receptors (Progesterone Receptor)IBA 01/2020 - 04/2006
20	Hormones (Hormone)IBA 01/2022 - 04/2006
14	Pharmaceutical PreparationsIBA 01/2021 - 01/2009
14	human ERBB2 proteinIBA 12/2020 - 05/2008
11	ParaffinIBA 01/2022 - 12/2002
11	Paclitaxel (Taxol)FDA LinkGeneric 01/2022 - 08/2005
11	Estrogens (Estrogen)FDA Link 12/2021 - 04/2006
11	AnthracyclinesIBA 11/2020 - 04/2007
11	ErbB Receptors (EGF Receptor)IBA 01/2018 - 02/2007
10	Formaldehyde (Formol)FDA Link 01/2022 - 01/2004
10	Carboplatin (JM8)FDA LinkGeneric 01/2022 - 07/2007
10	Trastuzumab (Herceptin)FDA Link 05/2021 - 04/2012
9	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2022 - 06/2004
9	taxaneIBA 01/2021 - 03/2009
8	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2022 - 08/2005
8	Immune Checkpoint InhibitorsIBA 12/2021 - 01/2017
7	Lapatinib (GW572016)FDA Link 05/2021 - 10/2012
7	Docetaxel (Taxotere)FDA Link 12/2018 - 03/2009
7	MicroRNAs (MicroRNA)IBA 01/2016 - 01/2012
7	Tamoxifen FDA LinkGeneric 12/2014 - 04/2006
6	LigandsIBA 01/2016 - 08/2011
5	Protein Isoforms (Isoforms)IBA 01/2020 - 08/2014
5	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2017 - 07/2007
5	Fluorouracil (Carac)FDA LinkGeneric 04/2012 - 06/2004
5	Keratin-5 (Keratin 5)IBA 03/2008 - 12/2002
4	EnzymesIBA 11/2020 - 01/2008
4	VimentinIBA 12/2018 - 02/2006
4	AntibodiesIBA 09/2017 - 08/2004
4	Phosphotransferases (Kinase)IBA 01/2017 - 04/2012
4	Complementary DNA (cDNA)IBA 11/2006 - 06/2002
3	ChromatinIBA 12/2021 - 01/2013
3	Fulvestrant (Faslodex)FDA Link 12/2021 - 10/2013
3	Keratins (Keratin)IBA 01/2018 - 08/2004
3	Transcription Factors (Transcription Factor)IBA 01/2018 - 11/2007
3	Epithelial Cell Adhesion MoleculeIBA 01/2017 - 02/2012
3	Epidermal Growth Factor (EGF)IBA 10/2015 - 06/2006
3	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 07/2015 - 06/2010
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 12/2014 - 03/2009
3	Cetuximab (Erbitux)FDA Link 03/2014 - 07/2007
3	Oncogene Proteins (Oncogene Protein)IBA 06/2010 - 01/2006
2	LipidsIBA 01/2022 - 09/2012
2	Bevacizumab (Avastin)FDA Link 01/2022 - 01/2015
2	Small Cytoplasmic RNAIBA 12/2021 - 01/2021
2	pertuzumabIBA 05/2021 - 08/2013
2	Monoclonal AntibodiesIBA 05/2021 - 12/2002
2	entinostat (MS 275)IBA 01/2021 - 11/2018
2	Androgen Receptors (Androgen Receptor)IBA 01/2021 - 01/2018
2	Small Interfering RNA (siRNA)IBA 11/2020 - 07/2006
2	AntigensIBA 01/2020 - 01/2017
2	Cyclin D1IBA 01/2019 - 09/2009
2	PhosphoproteinsIBA 12/2018 - 07/2013
2	PlatinumIBA 12/2018 - 01/2018
2	Trinitrotoluene (TNT)IBA 01/2018 - 09/2010
2	AsparagineIBA 01/2018 - 01/2018
2	Capecitabine (Xeloda)FDA Link 01/2018 - 04/2012
2	AmberIBA 01/2018 - 03/2016
2	Estrogen Receptor alphaIBA 01/2018 - 11/2007
2	lysophosphatidic acidIBA 04/2017 - 06/2009
2	tyrosine receptor (receptor, tyrosine)IBA 01/2017 - 10/2013
2	ProteomeIBA 01/2017 - 03/2016
2	Peptides (Polypeptides)IBA 03/2016 - 12/2007
2	A-Form DNA (A-DNA)IBA 01/2016 - 12/2014
2	Crystallins (Crystallin)IBA 10/2015 - 01/2006
2	Interleukin-8 (Interleukin 8)IBA 07/2015 - 01/2011
2	ChemokinesIBA 07/2015 - 01/2011

Therapy/Procedure

82	Therapeutics 01/2022 - 07/2006
39	Drug Therapy (Chemotherapy) 01/2022 - 08/2005
17	Neoadjuvant Therapy 01/2022 - 07/2003
9	Immunotherapy 01/2022 - 11/2016
4	Precision Medicine 01/2022 - 01/2016
4	Transplantation 09/2013 - 04/2008